Michael Craig Pine - Dec 4, 2023 Form 4/A - Amendment Insider Report for EyePoint Pharmaceuticals, Inc. (EYPT)

Signature
/s/ Ron Honig, Attorney-in-Fact
Stock symbol
EYPT
Transactions as of
Dec 4, 2023
Transactions value $
-$442,890
Form type
4/A - Amendment
Date filed
12/11/2023, 04:15 PM
Date Of Original Report
Dec 6, 2023
Previous filing
Jun 22, 2023
Next filing
Jan 9, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EYPT Common Stock Options Exercise $568K +45K +842.22% $12.62 50.3K Dec 4, 2023 Direct F1
transaction EYPT Common Stock Sale -$990K -45K -89.39% $22.00 5.34K Dec 4, 2023 Direct
transaction EYPT Common Stock Sale -$20.8K -1K -18.72% $20.79 4.34K Dec 4, 2023 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EYPT Stock Option (Right to Buy) Options Exercise $0 -45K -45% $0.00 55K Dec 4, 2023 Common Stock 45K $12.62 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Includes 2,159 shares acquired on January 31, 2023 and 2,184 shares acquired on July 31,2023 pursuant to EyePoint's 2019 Employee Stock Purchase Plan.
F2 This owned share transaction was inadvertently left off of the original Form 4 filing on December 6, 2023.
F3 The option to purchase will vest and become exercisable as follows: 25% at January 10th, 2023 and the remainder ratably, on a monthly basis, over the remaining three years.